Friday, May 31, 2013
The Leukemia & Lymphoma Society (LLS), a global voluntary health agency, is committing approximately $6 million to Valor Biotherapeutics, a joint venture of biotechnology companies ImmunGene and Caliber, to co-fund the completion of preclinical development, manufacturing and a phase I clinical trial for a novel fusion protein that may change the poor outcomes faced by many patients with indolent lymphomas who do not respond to standard therapy with rituximab.
The Christopher & Dana Reeve Foundation and Capstone National Partners announced a $2 million grant from the Department of Defense (DOD) to further support the expansion of translational research to find treatments for individuals living with spinal cord injury, including servicemen and women.
PharmAthene, a biodefense company developing medical countermeasures against biological and chemical threats, said the FDA has lifted the clinical hold previously placed on a proposed phase II study of SparVax, a next generation recombinant anthrax vaccine.
“Anthrax has been identified as one of the foremost potential biological threats to the nation,” said Eric I. Richman, president and CEO. “The U.S. government’s requirement for a recombinant anthrax vaccine for the civilian Strategic National Stockpile is an important national security imperative that remains unfilled. Next-generation anthrax vaccines like SparVax, which employ modern vaccine technology, offer the potential for improved convenience, cost-effectiveness, more rapid immunity, and the ability for large scale rapid delivery.”
Avillion, which focuses on clinical co-development of therapeutics, has expanded its leadership team, appointing Ramani Varanasi, MSc, MBA, chief business officer.
Varanasi has 18 years of biotechnology and pharmaceutical industry experience in structuring, negotiating and executing successful strategic alliances, licensing agreements and M&A transactions, as well as in business development, management and strategic leadership.